Schrödinger, Inc. (43Z)

Overview

Schrödinger, Inc. is a pioneering company that develops a sophisticated computational platform grounded in physics, which is designed for the discovery of novel molecules applicable in both drug development and materials science. Since its inception in 1990, Schrödinger has been operating out of New York, New York, undertaking ambitious endeavors in molecular discovery across two primary segments: Software and Drug Discovery. The Software segment is dedicated to revolutionizing molecular discovery in the life sciences and materials science industries through its proprietary software solutions. On the flip side, the Drug Discovery segment is committed to advancing a broad spectrum of preclinical and clinical programs either internally or in partnership with other entities. Catering to a global clientele, Schrödinger serves a wide range of industries, including biopharmaceutical firms, industrial companies, academic institutions, and government laboratories around the world.

Products and Services

• Software Licensing

Under the Software segment, Schrödinger offers licenses for its cutting-edge software designed to significantly enhance the process of molecular discovery. This software is strategically crafted for both life sciences and materials science sectors, streamlining and expediting the research and development process for a myriad of applications.

• Drug Discovery

In the Drug Discovery segment, Schrödinger emphasizes the development of a diversified portfolio of drug candidates. This portfolio spans various stages of the discovery and development process, ranging from preclinical studies to clinical trials. The company not only works on these programs internally but also collaborates with external partners to leverage collective expertise and resources, thereby fostering innovation and accelerating the journey of potential drugs from the laboratory to the marketplace.